


# K2 Global Equities Fund (Hedge Fund)

## 31 October 2018



	1 Month	3 Months	1 Year	3 Years (%pa)	Inception (%pa)	Inception Date
Performance (Net of Fees)	-5.2%	-5.1%	-3.9%	1.2%	1.3%	20-Jul-2015
Average Net Exposure	71.4%	77.4%	85.4%	81.3%	81.2%	

### Growth of \$10,000



Top 5 Stock Holdings	Current	Monthly Move
Elanor Investor Group	5.5%	+0.6%
Goldman Sachs Group Inc	4.4%	-0.9%
Metlifecare Ltd	4.2%	+0.0%
Pioneer Credit Ltd	3.5%	0.0%
Medical Developments International	3.2%	+0.7%

Month End Exposures	Current	Monthly Move
Communication Services	0.8%	-0.3%
Consumer	9.6%	-4.6%
Energy	1.5%	-5.3%
Financials	20.0%	-2.7%
Health Care	14.5%	+2.8%
Industrials	4.3%	-0.8%
Information Technology	7.6%	-1.6%
Materials	2.5%	-3.2%
Real Estate	5.1%	-0.4%
Utilities	0.6%	-0.1%
SHORTS	-4.9%	+1.2%
Number of Positions	51	-13
Gross Equity Exposure	71.4%	-17.4%
Cash Weighting	38.4%	+15.0%
Net Equity Exposure	61.6%	-15.0%
Currency Exposure Hedged of AUD	39.9%	-7.2%

### Commentary

The K2 Global Equities Fund returned -5.2% for the month of October while Global equity markets returned -5.6%.

Positive contributors to performance were few and far between given the sharp fall in global equity markets. Gains were made predominantly from our short positions including Genworth Mortgage Insurance in Australian and UK software automation company Blue Prism Group Plc as stock prices retreated. On the long side, Medical Developments Limited rallied over 15% after signing a significant distribution deal with Daiichi Sankyo, a major Japanese pharmaceutical company. The deal involves Daiichi making an upfront payment of AUD21m with additional milestone payments of AUD25m for the distribution rights to Pentrox in China. Since the start of 2018, 26 additional countries have received regulatory approval for Pentrox, taking the total number of approved countries to 38 as its globalisation gathers momentum. This number is expected to grow to over 70 countries by 2020.

Key detractors for the month included Seven Group Holdings, Metlifecare, CYBG PLC, Visa, Z-Energy, Norwegian Cruise Line and Lazard.

The Fund's net exposure was further reduced during the month to 62% after initially starting the month at 77%. We believe a more cautious approach is warranted as global economic growth decelerates. This is being driven by a number of factors including: Rising US interest rates, persistently high oil prices, geo-political events such as Brexit and Trade Wars and a shrinking of the Federal Reserve balance sheet. In addition, higher input costs from wages and tariffs will pressure corporate earnings, removing much of the foundation that helped propel equity markets higher.

The Fund currently holds a 40% hedged position to offset against any bounce in the Australian Dollar.

Fund Characteristics	
FUM	AUD \$13m
Portfolio Managers	Campbell Neal, David Poppenbeek, Josh Kitchen, Nicholas Leilt, James Soutter and Tony Sutton
Strategy	International Equities (Based on K2 Global High Alpha Fund)
Objectives	To deliver consistent absolute returns over the investment cycle with a focus on capital protection during periods of market declines.
Return Target	+10% pa over the long term.
Number of Stocks	Up to 120 stocks
Cash	Up to 100% of portfolio
Distributions	Annually
Management Fee	2.05%
Buy/Sell	Bought and Sold on the ASX market (ASX: KII)
Performance Fee	20.5% of the amount by which the NAV per unit exceeds the High Water Mark

**Nicholas Allen**  
Head of Distribution  
03 9691 6119  
nallen@k2am.com.au

**Sophie Gibbons**  
Head of Distribution  
03 9691 6117  
sgibbons@k2am.com.au

DISCLAIMER: Returns are shown after fees (including performance fees) and expenses have been deducted and assume the reinvestment of income distributions. Please note that past performance is not a reliable indicator of future performance. The information contained in this document is produced by K2 Asset Management Ltd ("K2") in good faith, but does not constitute any representation or offer by K2. It is subject to change without notice, and is intended as general information only and is not complete or definitive. K2 does not accept any responsibility, and disclaims any liability whatsoever for loss caused to any party by reliance on the information in this document. A product disclosure statement or information memorandum for general information on the funds referred to in this document can be obtained at [www.k2am.com.au](http://www.k2am.com.au) or by contacting K2. You should read the product disclosure statement and consider whether the product is appropriate for you before making a decision to acquire or continue to hold an interest in the fund. Fees referred to in this document are inclusive of GST and RITC and do not include expense recoveries.